Is it time to repair a fairly fast SAAB convertible? Testing an evidence-based mnemonic for the secondary prevention of cardiovascular disease by Chin, Jialiang et al.
 Is it time to repair a Fairly Fast SAAB Convertible?  
Testing an evidence-based mnemonic for the 
secondary prevention of cardiovascular disease. 
 
Mr Jialiang Chin,* Dr Jordan Fulcher,*  
Professor Alicia Jenkins, Professor Anthony Keech 
 
 
Correspondence to: 
National Health and Medical Research Council (NHMRC) Clinical Trials Centre 
University of Sydney 
Level 6 Medical Foundation Building 
92-94 Parramatta Rd, Camperdown, NSW 2050, Australia 
Email:  jordan.fulcher@ctc.usyd.edu.au 
Phone:  +61 2 9562 5000 
Fax:  +61 2 9562 5090 
 
*Co-first authors 
  
Keywords 
cardiovascular disease; acute coronary syndrome; secondary prevention; pharmacotherapy; 
evidence-based medicine 
  
  
Abstract 
Objectives: Optimising secondary prevention of cardiovascular disease has the greatest 
potential to reduce recurrent events, yet despite major guidelines there are ongoing 
treatment gaps.  FFSAABC (Fish oils, Fibrates, Statins, Aspirin, Angiotensin converting 
enzyme inhibitors or angiotensin 2 receptor antagonists, Beta blockers and Clopidogrel) is 
one mnemonic previously adopted to assist clinicians in remembering medications for use in 
secondary prevention. The aim of this narrative review is to examine the current evidence 
base for medications recommended for patients with established cardiovascular disease and 
the current applicability of this, or a revised mnemonic for their use.   
Study design:  Randomised controlled trials and systematic reviews were sought examining 
Fish oils, Fibrates, Statins, Aspirin, Angiotensin converting enzyme inhibitors or angiotensin 2 
receptor antagonists, Beta blockers or Clopidogrel vs placebo in secondary prevention. The 
emerging evidence base for other contemporary therapies including the P2Y12 inhibitors 
(Ticagrelor and Prasugrel) and aldosterone antagonists was also reviewed. 
Results: Definitive evidence supports the use of statins, aspirin, angiotensin converting 
enzyme inhibitors or angiotensin 2 receptor antagonists, and clopidogrel or newer P2Y12 
antagonists (ticagrelor or prasugrel) for the secondary prevention of cardiovascular disease. 
Aldosterone antagonists have strong evidence in the presence of systolic heart failure. There 
is a weaker evidence base for the routine use of omega-3 fatty acid supplementation 
although this therapy carries minimal harms. Fenofibrate reduces cardiovascular events in 
dyslipidaemic patients, with additional benefits in patients with diabetes.  
Conclusions: Mnemonic upgrading from a Fairly Fast SAAB Convertible to a Fairly Fast 
SA2A2B (Fish oils, Fibrate, Statin, Antiplatelets (Aspirin + Other), ACE/ARB, Aldosterone 
  
Antagonist, Beta-blocker) may help to ensure patients receive best practice evidence-based 
pharmacotherapies for the secondary prevention of cardiovascular disease.   
  
  
Introduction 
Acute coronary syndrome (ACS) is a substantial cause of morbidity and mortality, accounting 
for 75000 hospitalisations in Australia in 2010. Just over 1/3 of these hospitalisations were 
for recurrent events, accounting for nearly one half the overall economic cost of ACS and a 
20% absolute mortality rate – double that of those suffering their first event.1 Individuals 
who survive an ACS therefore stand to derive substantial absolute benefits from 
pharmacological interventions that reduce recurrent cardiovascular events, highlighting the 
importance and cost-effectiveness of secondary prevention. Despite national guidelines,2 
currently only a half to two thirds of eligible patients in Australia receive at least four out of 
five guideline based pharmacotherapies on hospital discharge following a diagnosis of ACS.3 
Mnemonics have been used as learning aids dating back to Ancient Greek and Roman times, 
classically representing a means of connecting a series of dissociated items into a unified 
whole. Medical education, characterised traditionally by endless lists of causes, differentials 
and treatments, has frequently adopted mnemonics for learning. To aid clinicians in 
remembering potentially useful therapies, our senior author adopted the mnemonic SAAB in 
the 1990s, which was extended to SAAB Convertible in 2001 and later Fairly Fast SAAB 
Convertible (FFSAABC) in approximately 2009. This mnemonic represents Fish oils, Fibrates, 
Statins, Aspirin, Angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor 
blockers (ARB), Beta-blockers and Clopidogrel. However, many new studies have been 
conducted in the last five years, in particular investigating fish oils, newer P2Y12 inhibitor 
medications and aldosterone antagonists. The purpose of this review is to evaluate whether 
the existing evidence supports the continued use of FFSAABC as a mnemonic for 
pharmacotherapy in the secondary prevention of CVD, or if a revision is appropriate. 
 
  
Fibrates 
Fibric acid derivatives typically reduce triglyceride concentrations by 30-50% and increase 
HDL cholesterol concentrations by up to 10%. A meta-analysis by Lee et al. of randomised 
controlled trials investigating fibrate therapy found that compared to placebo, fibrates given 
to secondary prevention patients with both hypertriglyceridaemia (defined as triglycerides > 
2.3mmol/L or nearest equivalent) and low HDL-C (defined as HDL-C < 1.03mmol/L or nearest 
equivalent) reduced the risk of cardiovascular events by 28%, noting there were no 
significant mortality reductions observed.4 In patients with neither lipid abnormality in the 
overall population (patients with CHD or diabetes) there was no effect of fibrates on 
cardiovascular events.  
In recent years fibrates used in patients with diabetes have also been shown to reduce the 
progression of retinopathy (37%), need for amputations (36%), and progression of 
nephropathy (with possible improvements), effects which are independent of baseline lipid 
profiles.5   
Fenofibrate is the only drug of this class safely recommended for concomitant 
administration with statins, due to increased risks of myotoxicity and rhabdomyolysis with 
other fibrates. The most frequently reported adverse effects are gastrointestinal, while there 
are with rare risks of pancreatitis (0.3%) and pulmonary embolism (0.4%).6  
Current evidence indicates fibrates are effective in the prevention of cardiovascular events 
without a clear mortality reduction, but benefits appear limited to patients with residual 
dyslipidaemia. There are additional pronounced microvascular benefits for people with 
diabetes. 
  
 
Fish oils 
Research arising from long term population studies linking high seafood intake with lower 
rates of cardiovascular events and mortality led to the isolation of omega-3 polyunsaturated 
fatty acids as the most likely active constituent. However randomised trials examining 
cardiovascular outcomes with fish oils have produced conflicting evidence. A systematic 
review in 2012, including twenty trials and data from around 63000 trial participants, found 
fish oils had no effect on the primary composite cardiovascular outcome.7 Amongst the 
thirteen trials reporting on cardiovascular mortality, there was a significant 14% reduction in 
risk overall, noting significant trial heterogeneity (I2=60.7%, P=0.001). No effect was seen on 
all-cause mortality, sudden cardiac death or individual cardiovascular outcomes. The two 
individual trials with results most supportive of a positive effect of fish oil supplementation 
have been the primary prevention Japan Eicosapentaenoic acid Lipid Intervention Study 
(JELIS) and secondary prevention Gruppo Italiano per lo Studio della Sopravvivenza 
nell'Infarto (GISSI) Prevenzione study, both of which were open-label. Some factors 
suggested as potentially contributing to trial heterogeneity have also included baseline 
triglyceride levels (greater benefits with higher baseline triglyceride levels); age of trial 
participants (greater benefits in younger patients); and the presence of hypertension or 
diabetes (greater benefits in patients without these comorbidities).7 Several trials in this 
meta-analysis had control groups which were on a Mediterranean diet, used olive oil as a 
control or had a fish rich diet, all of which could have masked the benefits of omega-3 
supplementation with their own cardio-protective effects. A linear response to fish oil intake 
and CVD protection has never been established, suggesting supplementation beyond a 
certain level of intake may not confer additional benefits.8 
  
The commonest side effect of oral fish oil use is gastrointestinal upset (fishy aftertaste, 
reflux and diarrhoea), although this can often be lessened with enteric coating. Limited 
evidence exists regarding serious adverse effects of omega-3 fatty acids. No effect on cancer 
incidence has been reported in meta-analyses of eight randomised studies from a systematic 
review.7  
Currently the evidence base for the use of fish oils to reduce cardiovascular or mortality 
endpoints is limited, and general conclusions are that the available evidence is not adequate 
to strongly support the use or cessation of omega-3 fatty acids in the secondary prevention 
of CVD.7 Australian secondary prevention guidelines (Reducing Risk in Heart Disease, 2012) 
recommended an average daily intake of 1g of fish oils through either dietary or 
supplemental means, and only specifically recommended capsules/liquid for those with 
elevated triglycerides.2 The AHA/ACCF Secondary Prevention Guidelines (2011) state it “may 
be reasonable” to recommend omega-3 fatty acids from fish or fish oil supplements.9  
 
Statins 
A large-scale individual patient meta-analysis of 27 randomised controlled trials of statin 
therapy by the Cholesterol Treatment Trialists’ Collaboration has shown that amongst 
~100000 randomised trial patients with prior cardiovascular disease, statins reduced the risk 
of major cardiovascular events by 23% per 1.0mmol/L reduction in LDL-cholesterol (LDL-C), 
irrespective of baseline LDL-C level.10 Amongst five randomised trials of patients with known 
ischaemic heart disease comparing more intensive statin regimens to less intensive 
regimens, more intensive dose statin therapy reduced LDL cholesterol concentrations by an 
additional 0.51mmol/L and was associated with a further 15% reduction in the risk of major 
vascular events.11 Amongst all trials, allocation to statin/more intensive statin therapy 
significantly reduced the risk of non-fatal MI and coronary revascularisation by about a 
  
quarter and ischaemic stroke by about a fifth (with a 15% reduction in any stroke) per 
mmol/L LDL-cholesterol reduction. The risk of cardiovascular mortality was reduced by 14% 
and all-cause mortality by 10% per mmol/L LDL cholesterol reduction. Amongst these 
endpoints the relative benefits of statin therapy were maintained across all levels of 
absolute cardiovascular risk.10 Since patients with previous vascular disease have the highest 
absolute risks of recurrent cardiovascular events, they therefore stand to benefit the most 
from statin/more intensive treatment.  
Potential adverse effects of statins include muscle conditions (ranging from myalgia to 
rhabdomyolysis), new onset type 2 diabetes mellitus, a very small increase in haemorrhagic 
stroke and transient reversible memory impairment.12 Myalgia, by far the most common 
adverse effect, occurs in 1-5% of patients, whilst myopathy occurs in 0.1-0.5%  and 
rhabdomyolysis in 0.01%.12 Statin use has been associated with an increase in rate of 
diagnosis of incident diabetes by 9% in a meta-analysis of trials comparing statin to 
placebo,13 and by 12% in a meta-analysis of trials comparing more vs. less intensive statin 
therapy.14 This association is stronger in patients who are older and appears to be more 
common amongst patients with other risk factors for diabetes such as hypertension, higher 
BMI, higher baseline fasting glucose levels and higher triglycerides.12 Despite the potential 
risk for new diabetes, which remains to be more definitively researched, the relative and 
absolute cardiovascular benefits from statin therapy vastly outweigh the risks associated 
with developing diabetes.10  
There have been post marketing surveillance reports of a possible rare association of statin 
treatment with mild cognitive impairment that appears to be reversible over a median time 
of 3 weeks after treatment withdrawal. No adverse link between statin treatment and 
dementia has been found despite some false media reports to the contrary. Randomised 
  
trials of statin therapy which specifically examined for cognitive changes did not identify any 
adverse effects.12 
Previous concerns about increases in cancer with statins have been convincingly refuted, at 
least within the median five year timeframe of 27 randomised trials.10 In addition, there is 
now long term follow-up data from previous statin trial participants indicating no worse 
outcomes out to over 10 years for cancer incidence or death amongst those originally 
randomised to statin therapy compared to those allocated to placebo.15 
Current evidence strongly supports the use of statins in the secondary prevention of 
cardiovascular events, particularly as National Heart Foundation targets of LDL-C 
concentrations <1.8mmol/L for secondary prevention are difficult to achieve with lifestyle 
changes alone.2 Adverse events are infrequent and serious events are extremely rare. Whilst 
there is debate regarding balancing absolute benefits against possible adverse events for 
low risk primary prevention, there should be no question about net benefit for secondary 
prevention, where the profound cardiovascular benefits of therapy firmly outweigh the risks. 
 
Aspirin 
An individual patient data meta-analysis by the Anti-thrombotic Trialists of 16 secondary 
prevention trials showed that aspirin reduced annual rates of serious vascular events 
(myocardial infarction, any stroke or vascular death) by 19%, major coronary events by 20%, 
any stroke by 19%, cardiovascular mortality by 9% and all-cause mortality by 10%.16 
Emerging data supports additional non-cardiovascular benefits of aspirin in reducing the 20-
year risk of solid cancers (20%).17  
Haemorrhage is the main hazard of aspirin. The Antithrombotic Trialists calculated an 
increased risk of any major bleed with aspirin of 169%. Small absolute increases in 
  
haemorrhagic stroke are offset by much larger reductions in ischaemic stroke producing a 
net benefit with aspirin therapy, and no effect on fatal stroke.16 Another meta-analysis of six 
secondary prevention trials using lower-dose (≤325mg) daily aspirin estimated an increased 
risk of gastrointestinal bleeds by 250%, representing an absolute increase from 0% to 2% 
(+/- 1.4%) over four years of follow up, with no deaths.18 A comparison of the relative 
numbers needed to treat determined 1.5 deaths were prevented with aspirin for each GI 
bleed (of any severity) caused.  
High-dose aspirin has not been shown to increase clinical benefits whilst definitely increasing 
the risk of bleeding complications.19 Therefore in view of overwhelming evidence supporting 
the use of aspirin for secondary prevention of cardiovascular events, administering low-dose 
aspirin (75-150mg/day) will minimise the risk of adverse effects without compromising 
benefits.  
 
ACE Inhibitors and Angiotensin Receptor Blockers 
A large scale individual patient data meta-analysis of ~100000 pooled trial participants 
showed ACE inhibitors given in the acute phase (0-36h from symptom onset) of an MI 
significantly reduced 30 day mortality rates by 7%.20 Another individual patient data meta-
analysis pooling data from three long term trials amongst patients post MI with left 
ventricular dysfunction or clinical heart failure showed that ACE inhibitors reduced the risks 
of recurrent MI by 20%, readmission for heart failure by 27% and all-cause mortality by 26% 
over four years of follow-up.21 Similar overall proportional benefits have been demonstrated 
in patients post MI with preserved ejection fractions.22  
Trials comparing an angiotensin receptor blocker to an ACE inhibitor post MI with LV 
impairment have overall shown no difference in clinical benefits between the two classes in 
terms of reductions in MI, hospitalisation for heart failure, cardiovascular death and all-
  
cause mortality.23,24 In contrast to some evidence in chronic heart failure patients, no 
additive benefits of combining the two classes for secondary prevention has been 
demonstrated, whilst the risk of side effects is increased.24   
Potential adverse effects of either ACE inhibitors or ARBs include hypotension, 
hyperkalaemia, a reduced glomerular filtration rate and rare but potentially fatal 
anaphylactoid reactions, while cough has a well identified increased risk of about 10% with 
ACE inhibitors.21,25 These effects are nearly always reversible with treatment withdrawal, if 
necessary. In most cases hyperkalaemia develops in the presence of other comorbidities or 
medications and can be managed without ceasing the ACE inhibitor or ARB. Similarly, 
glomerular filtration rates can fall in some patients (usually with comorbidities such as 
chronic kidney disease or bilateral renal artery stenoses) but both medication types are 
nevertheless reno-protective and recommended for use in most patients, even with chronic 
renal failure.  
Overall, treatment with either an ACE inhibitor or ARB has clear evidence for cardiovascular 
event and mortality reductions after an acute coronary syndrome, irrespective of the 
presence of systolic ventricular impairment. There is no compelling evidence for combining 
them in this setting, which risks hyperkalaemia without added benefit.  
 
Beta Blockers  
Beta-blockers have longstanding evidence of efficacy in secondary prevention. A systematic 
review of nearly 25000 patients included in 31 long term randomised trials found beta-
blockers reduce the risk of all-cause mortality by 23%. The number needed to treat over one 
year to prevent one death was 84 patients and to prevent one non-fatal cardiac reinfarction 
was 107.26 Mortality benefits have also been established in populations in which underuse 
may be more common including patients aged ≥80, patients with COPD or diabetes, patients 
  
with resting heart rates <70 or systolic BP<100 and lower risk patients without any 
complications.27 
A meta-regression analysis of 14 beta blockade trials found that reductions in cardiac death, 
sudden death and all-cause death as well as non-fatal MI were significantly related to the 
extent of heart rate reduction achieved.28 However, a recent large randomised study 
investigating Ivabridine, a purely chronotropic agent, in patients with stable CAD found that 
despite significant heart rate reductions in the Ivabradine arm, the combined cardiovascular 
endpoint was not reduced, suggesting the cardiovascular benefits of beta blockers are not 
attributable solely to heart rate reductions.29  
In patients with heart failure from systolic dysfunction (due to any cause but including 
myocardial infarction) a systematic review and network meta-analysis showed beta-blockers 
reduced all-cause mortality by 29% without any significant difference shown between the 
long acting beta-blockers indicated for use in this setting.30 
The optimal long term duration of beta blockade therapy after MI is not currently known. 
Registry data and observational studies suggest reductions in cardiovascular events may 
extend out to four years, with stronger evidence extending to six years in higher risk patients 
such as those with heart failure.31,32 In patients with normal left ventricular function, 
AHA/ACCF secondary prevention guidelines recommend beta-blocker therapy for at least 
three years and suggest ongoing treatment is reasonable (Class IIa, Level of evidence B).9 
Recently reported French registry data suggested there may be no additional mortality 
benefits from beta blockers beyond the first 12 months after an MI in patients with 
preserved systolic function (LVEF>40%), although likely confounding of this observational 
data has been raised as a major limitation in drawing strong conclusions.33  
Effects of beta-blockade which can prompt discontinuation include bradycardia and 
hypotension. Rarely other adverse events can require cessation such as fatigue (1.5%), 
depression (0.4%), reduced libido (0.2%), dizziness, vivid dreams and cold extremities.26 
  
Beta blockers have strong and longstanding evidence for cardiovascular event and mortality 
reductions in secondary prevention patients, particularly in patients with heart failure, 
noting there is some uncertainty about an ongoing benefit in patients with preserved 
systolic function beyond three years, and possibly sooner. 
 
Clopidogrel / Other P2Y12 Antagonists (Ticagrelor, Prasugrel) 
A systematic review and meta-analysis of randomised trials of dual antiplatelet therapy in 
patients with acute coronary syndrome or undergoing percutaneous coronary intervention 
showed the addition of clopidogrel to aspirin reduced the risk of cardiovascular mortality by 
7%, recurrent MI by 20% and stroke by 16% without any effect on the risk of intracranial 
haemorrhage.34 Conflicting findings regarding bleeding risks have been reported. A recent 
meta-analysis amongst mostly secondary prevention trials reported a 40% increased relative 
risk of major bleeding using both clopidogrel and aspirin compared to aspirin alone,35 while 
in other instances no increased risk was seen.36 Loading doses likely contribute to bleeding 
risk - a higher loading dose of clopidogrel of 600mg (compared to 300mg) is recommended 
before percutaneous intervention in clopidogrel naïve patients due to improved 
cardiovascular outcomes, but this is at the expense of a higher major bleeding risk.37 
In recent years two additional P2Y12 inhibitors have emerged as potential alternatives to 
clopidogrel as a second antiplatelet agent: prasugrel and ticagrelor. Like clopidogrel, 
prasugrel is an irreversible thienopyridine P2Y12 inhibitor which is ingested as a pro-drug 
and metabolised by cytochrome P450 enzymes to its active form. It has a faster onset and 
greater degree of platelet inhibition than clopidogrel due to more efficient metabolism into 
its active form, and reduced function CYP polymorphisms do not appear to impact on 
prasugrel metabolism like they do up to 40% of patients who take clopidogrel.38 In TRITON-
TIMI 38, a randomised trial of 13600 people presenting with moderate-high risk ACS and 
  
scheduled for PCI, allocation to prasugrel compared to clopidogrel resulted in 19% fewer 
combined cardiovascular events, 24% fewer MIs and 52% fewer stent thromboses, with no 
effect on cardiovascular or all-cause mortality at 15 months follow-up.39 This was at the 
expense of a 32% increase in non-CABG related TIMI major bleeding and a 473% increase in 
CABG related TIMI bleeding. Post-hoc subgroup analyses suggested that patients with a 
previous stroke or TIA were at a net risk of harm taking prasugrel, whilst those aged age≥75 
or with body weight<60kg appeared to have a neutral outcome. As a consequence prasugrel 
is contraindicated in patients with a previous stroke or TIA and a lower dose is 
recommended for those aged ≥75 or with body weight <60kg.40  
The TRILOGY-ACS trial compared prasugrel to clopidogrel in 7200 patients with either 
unstable angina or NSTEMI for medical management excluding patients with previous 
stroke/TIA.41 Over 30 months of follow up there was no difference between prasugrel and 
clopidogrel in all cardiovascular, mortality and bleeding outcomes.    
In terms of non-bleeding adverse events, hypersensitivity reactions are identified with all 
thienopyridines (clopidogrel and prasugrel). Clopidogrel reactions occur in about 1-2% of 
patients and mostly manifest within the first week of treatment as a diffuse erythematous 
progressively confluent rash.42 Desensitisation can be attempted in mild cases. More severe 
outcomes including anaphylaxis are very rare. Substitution with another thienopyridine in 
the event of hypersensitivity is not recommended. 
Ticagrelor is a directly acting reversible P2Y12 inhibitor which has both a more rapid onset of 
effect and achieves a greater level of platelet inhibition than clopidogrel.43 In the PLATO trial 
which compared ticagrelor to clopidogrel in ACS patients, ticagrelor reduced the rates of the 
primary composite cardiovascular endpoint by 16%, myocardial infarction by 16%, stent 
thrombosis by 33%, cardiovascular death by 21% and all-cause mortality by 22%.43 There 
was no difference in overall major bleeding events or fatal bleeding between the two 
treatments. Subgroup analyses have demonstrated similar net benefits irrespective of 
  
revascularization status, age (including those ≥75), diabetes, renal failure or previous 
TIA/stroke.44  
Ticagrelor can cause a non-pathological dyspnoea which is mostly a single self- limiting event 
early after treatment is commenced. It occurred in 5% more patients than clopidogrel in 
PLATO and 0.9% of patients discontinued treatment because of dyspnoea.43 Patients 
reporting dyspnoea with ticagrelor had the same cardiovascular and mortality benefits as 
those without dyspnoea without evidence of altered pulmonary function. It is thought the 
mechanism for these symptoms may relate to increased extracellular adenosine levels from 
inhibition of adenosine reuptake. In PLATO ticagrelor also caused more ventricular pauses 
(≥3s) than clopidogrel (5.8% vs 3.6%) in the first week of treatment whilst a month later 
there were no differences between treatment groups.43 Despite this there was no difference 
in the incidence of bradycardic adverse events, including syncope, pacemaker insertion or 
cardiac arrest.  
Overall the evidence base clearly supports international guideline recommendations that 
any patient with acute coronary syndrome be treated with dual antiplatelet therapy for 
twelve months, irrespective of revascularisation status. European guidelines (STEMI 2011,  
NSTEMI 2012) management recommend the use of Ticagrelor or, if coronary anatomy is 
known and PCI planned, Prasugrel over the use of Clopidogrel.45  American society guidelines 
(STEMI 2013, UAP/NSTEMI 2012) recommend the use of any of these three agents without 
preference, noting that prasugrel is not recommended for UA/NSTEMI patients in whom 
conservative management is planned.9 Australian secondary prevention guidelines make 
similar recommendations.2 
 
  
Aldosterone Antagonists 
Randomised controlled trials investigating aldosterone antagonists in patients with systolic 
heart failure have demonstrated significant reductions in all-cause mortality, driven by 
reductions in cardiovascular mortality, including sudden cardiac death.46,47 Hospitalisations 
for heart failure are also significantly reduced. Apart from reduced hospitalisations for heart 
failure, other cardiovascular benefits were not seen in a recently published study amongst 
patients with heart failure and a preserved ejection fraction.48 As a consequence major 
international guidelines (ACC/AHA Secondary prevention 20119, ESC STEMI 201245) 
recommend the use of either spironolactone or eplerenone in patients suffering from severe 
systolic heart failure of any aetiology (LVEF≤35% and NYHA class II-IV with some additional 
provisions for class II patients) or STEMI patients with LVEF≤40% on an ACE inhibitor and 
beta blocker and with heart failure signs or diabetes.  
Of note all these trials excluded patients with hyperkalaemia (K≥5.0mmol/L) or moderate or 
worse renal impairment (eGFR<30mL/min/1.73m2 or serum Cr>221µmol/L) due to the 
increased risk of hyperkalaemia with aldosterone antagonists, particularly in the presence of 
renal failure. Other endocrine side effects are possible including gynaecomastia, menstrual 
irregularities and increased libido. Eplerenone carries a much lower risk than spironolactone 
of these hormonal effects due to greater receptor specificity, but is more expensive. 
Overall evidence supports prescription of aldosterone antagonists in secondary prevention 
patients with systolic heart failure, with significant mortality reductions. Renal function must 
be considered prior to prescription of either agent, whilst the endocrine side effect profile is 
more favourable for eplerenone than spironolactone. 
  
 
Other Non-Pharmacological Interventions 
Lifestyle interventions including smoking cessation, participation in exercise based cardiac 
rehabilitation, increased physical activity and avoiding excess alcohol consumption 
significantly reduce the risk of all-cause mortality. Annual influenza vaccination and dietary 
modification, particularly adopting a Mediterranean type diet, have both been showed to 
reduce major vascular events. Screening for depression is also important due to a strong 
association between depression and increased cardiovascular mortality after a myocardial 
infarction.2  
 
Discussion 
Whilst treatment prescription in medicine will always require an individualised approach 
there are notable ongoing deficiencies in the prescription of evidence based treatments for 
cardiovascular disease, in terms of overall rates and regional discrepancies. Mnemonics are 
frequently used in medicine to assist learning and rapid recall, and have the potential to aid 
clinicians in this regard. FFSAABC, a letter based mnemonic adopted over the last decade for 
treatments used in the secondary prevention of  cardiovascular disease, has been re-
examined in this review in light of updated evidence.  
There is currently strong evidence to support the use of statins, aspirin, ACEI/ARBs, β-
blockers and clopidogrel in the secondary prevention of cardiovascular disease. The newer 
P2Y12 inhibitors Ticagrelor and Prasugrel have indications for use as a substitute at least, if 
not in preference to clopidogrel in various settings. Aldosterone antagonists have strong 
evidence for reducing cardiovascular events and mortality amongst patients with moderate-
severe systolic heart failure. Fenofibrate is effective at reducing events in dyslipidaemic 
  
patients, irrespective of the presence of cardiovascular disease, noting that secondary 
prevention patients have a much higher absolute risk of future events and therefore stand 
to benefit more. It also prevents several microvascular diabetic complications. The evidence 
for fish oil supplementation is somewhat less definitive, but a small cardiovascular mortality 
benefit is suggested and potential harms are minimal. It has been estimated the combined 
prescription of evidence based pharmacotherapy together with lifestyle modification 
measures would reduce the post-ACS risk of recurrence by more than 50%.49  
Conclusion 
Effective secondary prevention of CVD can substantially reduce mortality and morbidity in 
Australia. It is important to ensure that clinicians in both hospital and community settings 
are prescribing evidence-based therapies, and are facilitating a high rate of patient 
adherence.  Considering the current pharmacologic evidence base for secondary prevention, 
upgrading from a Fairly Fast SAAB Convertible to a Fairly Fast SA2A2B (Fish Oils, Fibrate, 
Statin, Antiplatelets (Aspirin + Adjuvant Other Antiplatelet), ACE inhibitor/Angiotensin 
Receptor Blocker, Aldosterone Antagonist and Beta-blocker) appears to be timely. 
  
  
Table and Figure Legend. 
Figure 1. A Fairly Fast SAAB Convertible. Time to upgrade? 
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